ERBB2 and gastric cancer: Patients with HER2-overexpressing GC benefit from treatment with the anti-HER2 antibodies [1]. Multiple clinical studies of the targeted agent trastuzumab have proved that the application of surface antigen HER2 may serve as a target for adoptive cell transfer (ACT) therapy [8–10].